PRDM9 and neoplasm: The enhancer of zest homolog 2 (EZH2), a family member of the histone methyltransferases (HMT), can promote the cancer development through the catalyzation of the trimethylation of lysine at position 27 of histone H3, resulting in the suppression of downstream tumor suppressor genes [58].